TPWA
CSTL icon

Twin Peaks Wealth Advisors’s Castle Biosciences CSTL Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$25 – 675
2026
Q1 		$25 Buy
+1
New +$33 ﹤0.01% 2336
2025
Q3 		– Sell
-1
Closed -$19 – 599
2025
Q2 		$19 Buy
+1
New +$19 ﹤0.01% 2252

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's CSTL Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 1 share — an estimated $25 sold.

Twin Peaks Wealth Advisors first reported a position in CSTL in Q2 2025 and held it in 2 quarters. The position peaked at $25 in Q1 2026. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 1 Castle Biosciences share in Q2 2026, an estimated $25.
  • Twin Peaks Wealth Advisors first reported a position in Castle Biosciences in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Castle Biosciences position peaked at $25 in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.